Abstract:A cascade self‐uncloaking nanoassemblies (SRC) based on chemogene combination therapy is developed to tumor NIR‐II imaging and simultaneously increase tumor immunogenicity by immunogenic cell death (ICD) effect and regulation of STING pathway, reversing immunosuppressive tumor microenvironment by systemic activation of innate immune and adaptive immunity, ultimately elevating PD‐L1‐resistant CRC immunotherapy. CRISPR/Cas13a is a powerful genome editing system for RNA knockdown that holds enormous potential for cancer treatment by targeting currently undruggable oncogenes or immune checkpoints. However, the precise intratumoral activation of CRISPR/Cas13a to maximize the therapeutic efficiency while guaranteeing biosafety remains a daunting challenge. Here, a cascade self‐uncloaking nanoassembly (SRC) based on a dual‐prodrug comprising SN38 and Cas13a/RNP is developed, and the external encapsulation is performed by coating with a ROS‐responsive probe, which is stimulated by the tumor microenvironment to achieve the efficient NIR‐II imaging by CH10055 due to disaggregation into single molecules, while the second release of prodrug in the hypoxic environment enables targeted controlled release. SN38 not only induces immunogenic cell death (ICD), but significantly combats the immunosuppressive microenvironment of colorectal cancer in combination with the RNA editing targeting the novel immune checkpoint TIM3 to regulate the cGAS‐STING pathways, resulting in synergistic activation of both innate and adaptive immunity. The treatment of SRC exhibits a tenfold increase in tumor regression of α‐PD‐L1 in PD‐L1‐resistant orthotopic and xenograft models by inducing effective tumor immune infiltration. These results demonstrate the feasibility of using CRISPR/Cas13a in cancer treatment, and SRC holds immense promise as a neoadjuvant strategy for enhancing CRC immunotherapy.

Aptamer/Peptide‐Functionalized Genome‐Editing System for Effective Immune Restoration through Reversal of PD‐L1‐Mediated Cancer Immunosuppression

Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

Genome Editing of PD-L1 Mediated by Nucleobase-Modified Polyamidoamine for Cancer Immunotherapy.

Dual‐Locking Nanoparticles Disrupt the PD‐1/PD‐L1 Pathway for Efficient Cancer Immunotherapy

Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting Β-Catenin to Remodulate Cancer Cell Properties.

Programmable Unlocking Nano‐Matryoshka‐CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response

Reversal Of Tumor Malignization And Modulation Of Cell Behaviors Through Genome Editing Mediated By A Multi-Functional Nanovector

Self-Assembled Plasmid Delivery System For Ppm1d Knockout To Reverse Tumor Malignancy

A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.

Generation of Cancer-Specific Cytotoxic PD-1- T Cells Using Liposome-Encapsulated CRISPR/Cas System with Dendritic/Tumor Fusion Cells

Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid to Mediate Antitumor Genome Editing

Time-programmed activation of CD47 disruption and immunogenic cell death with Cas9 ribonucleoprotein nanocapsule for improved cancer immunotherapy

Precise RNA Editing: Cascade Self‐Uncloaking Dual‐Prodrug Nanoassemblies Based on CRISPR/Cas13a for Pleiotropic Immunotherapy of PD‐L1‐Resistant Colorectal Cancer

Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy

A Smart DNA Nanoassembly Containing Multivalent Aptamers Enables Controlled Delivery of CRISPR/Cas9 for Cancer Immunotherapy

Photo‐Enhanced CRISPR/Cas9 System Enables Robust PD‐L1 Gene Disruption in Cancer Cells and Cancer Stem‐Like Cells for Efficient Cancer Immunotherapy

In Vivo Gene Editing of T-cells in Lymph Nodes for Enhanced Cancer Immunotherapy

Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells

Dual-Responsive Core-Shell Tecto Dendrimers Enable Efficient Gene Editing of Cancer Cells to Boost Immune Checkpoint Blockade Therapy